BACKGROUND: Noninvasive cardiac output (CO) monitoring is possible by indocyanine green (ICG) dilution measured by pulse dye densitometry (PDD). To validate the precision of this method, we compared hemodynamic variables derived from PDD (DDG-2001, Nihon Kohden, Japan) with those derived from simultaneously taken arterial blood ICG concentrations. METHODS: In 20 patients (6 M/14 F), ASA I or II, 36 sessions were performed (n ϭ 24 with the PDD-finger probe, n ϭ 10 with the PDD-nose probe). After IV administration of 10 mg ICG, 34 arterial blood samples were taken during each session, with 20 samples taken during the first 2 min. CO, central blood volume (CBV), and total blood volume (TBV) were calculated independently from ICG and PDD and the results compared between methods using Bland-Altman analysis. The results are reported as mean difference (bias) and limits of agreement (LOA ϭ Ϯ 2 sd). RESULTS: PDD using the finger probe underestimated CO (LOA) by 5% (Ϫ56% and 47%); overestimated CBV by 21% (Ϫ54% and 96%) and underestimated TBV by Ϫ15% (Ϫ38% and 8%). PDD using the nose probe overestimated CO (LOA) by 30% (Ϫ67% and 127%); CBV by 48% (Ϫ98% and 193%) and underestimated TBV by Ϫ10% (Ϫ47% and 27%). CONCLUSION: Despite the permissible bias, the wide LOA of the PDD-derived hemodynamic variables CO and CBV, compared with those simultaneously obtained by invasive arterial ICG measurements, suggest that PDD is unsuitable for evaluation of cardiovascular variables in the individual patient. Hence, the reliability and clinical use of this method seem limited.
Noni nvasive cardiac output (CO) monitoring has gained increasing clinical attention in recent years. Various methods have been developed, based on different techniques, with variation in reliability and clinical applicability. Pulse dye densitometry (PDD) uses the indicator dilution technique and requires only IV access. The indicator indocyanine green (ICG) is confined to the intravascular space due to its hydrophilic character and binding to plasma proteins and is cleared from the blood through the liver. 1 ICG has been often used to determine cardiovascular variables, such as CO, 2,3 cardiac index, blood volume, 4-8 liver blood flow, 9 -11 and lung uptake of drug components such as lidocaine 12 through dye dilution. With the introduction of PDD, an adaptation of pulse spectrophotometry, it became possible to measure ICG noninvasively by means of transcutaneous spectrophotometry using a finger or nose probe. 13 Three validation studies of the measurement of the arterial blood ICG concentration versus PDD have been published. [13] [14] [15] In these studies, blood samples were taken after recirculation had taken place. However, the phase of initial mixing, before recirculation of the dye, is the period in which the data are gathered for the estimation of CO and central blood volume (CBV), since the area under the first pass curve is needed for the calculation of these variables. In the study published by Sakka et al., 16 intravascular measurement of ICG using a fiberoptic device showed good agreement with transcutaneous measurement of ICG for the determination of total blood volume (TBV), moderately for CBV and could not be performed for CO because of inaccurate detection of the first-pass curve. Consequently, validation of transcutaneous measurement of ICG by PDD versus ICG concentration measurements in arterial blood during the initial mixing phase is not available.
To evaluate the noninvasive measurement of ICG using PDD, we compared, in a group of patients, the ICG data measured using the PDD finger or nose probe to the ICG concentrations in arterial blood and compared the cardiovascular variables derived by these two methodologies.
METHODS

Study Design and Subjects
The ICG concentrations determined noninvasively by PDD and invasively in arterial blood were taken from patients who participated in either of two yet unpublished pharmacological studies. In 10 patients ICG concentrations were measured using the PDD finger probe, and in 10 other patients the nose probe was used. The studies were performed after obtaining approval from the Medical Ethics Committee of the Leiden University Medical Centre and the patients' written informed consent. The patients were ASA I or II and participated in the study before elective surgery. Exclusion criteria included a medical history of severe cardiovascular, respiratory, renal, hepatic, neurological or psychiatric disease, use of antihypertensive or antiarrhythmic medication, pregnancy or lactation, and a history of hypersensitivity to amide local anesthetics or ICG.
Before the measurements, a large venous cannula was inserted in the fossa cubiti and the radial artery was cannulated for gathering blood samples with a 22 G cannula. Placement of the finger probe was on the index finger, and the nose probe was on the right nasal wing. Cooling of the extremities was prevented to maintain signal quality. An experimental session started only when the PDD indicated a sufficient signal quality as measured by the finger or nose probe. Sufficient signal quality was judged a minimum of 2 out of 5 U as indicated on the DDG-2001. Each session started with the IV administration of 10 mg ICG (Infracyanine, Laboratoires SERB, Paris, France), followed by a rapid bolus of 20 mL of saline. A computer-controlled syringe pump with fraction collector drew arterial blood samples at 3-s intervals for the first minute, and at 10 s intervals for the second minute. Eight more samples were drawn manually up to 15 min after administration of the ICG bolus dose. The sampling system consists of a disposable sampling set, an automatic sampler and a carrousel with test tubes. The automatic sampler is a custom-made device that can move a syringe plunger to a set volume and moves a stopcock in coordination with sampling. The sampler is connected to a computer that times the sampling. Because of limitations in blood flow in the radial artery, the sampling rate is maximally 1 per 3 s. The carrousel moves synchronous to the sampling. The disposable sampling system consists of a syringe with a stopcock, extension tubing between the patient and the sampling syringe, and extension tubing to the test tubes mounted on the carrousel. The extension tubing to the patient is connected with a stopcock to the intraarterial catheter. The volumes in the extension tubes with the stopcocks have a dead-space volume of 1.8 mL. The sampling volume was set to 1.8 mL and is thus identical to the dead-space in the extension tubes. Each sampling cycle consisted of drawing the sample from the patient, turning the stopcock on the syringe and then ejecting the content of the syringe to the extension tube to the test tubes. Since the movement of blood in the system is fully controlled, mixing of samples in the tubing is unlikely and each sample represents the concentration at the sampling time. The blood samples were collected in heparinized glass tubes and processed immediately.
The patients in whom the finger probe was used for determination of ICG concentrations underwent up to three repeated measurements in the same session separated by a time period of at least 15 min to allow for dye excretion. During each measurement, patients were awake and in a hemodynamically stable condition. In the patients in whom the nose probe was used for the determination of ICG concentrations, single measurements were performed because patients were studied during induction of anesthesia.
Measurements of ICG in Blood
The concentrations of ICG were determined in whole blood using high performance liquid chromatography (Separations analytical instruments, Hendrik-Ido-Ambacht, The Netherlands; column: Ultrasphere ODS 4.6 ϫ 7.5 cm 244254, Beckman Coulter, Mijdrecht, The Netherlands) with ultraviolet and fluorescence detection. For each patient, a calibration curve was constructed, using the patients own blood before injection of ICG. The fluorescence settings were as follows: excitation at a wavelength of 780 nm and the emission wavelength at 810 nm with a gain of 100. ICG was also measured at 777 nm, its peak in the spectrum. Both ICG and its degradation product were identified by a diode array (Photodiodedetector PDA 100, Dionex, Amsterdam, The Netherlands). The detection limit of the whole blood assay for ICG was at 0.15 or 0.2 mg/L. The coefficient of variation was Ͻ6% over the range from 0.5 to 10.45 mg/L.
Data Collection and Processing
PDD was performed using the DDG-2001 A/K (Nihon Kohden, Tokyo, Japan). Data were transferred to a laptop computer and imported into a spreadsheet program (Excel 2000, Microsoft Corporation, Seattle, WA). Arterial blood concentrations were imported into the same spreadsheet program to undergo further analysis.
CO was calculated by dividing the administered ICG dose by the area under the first pass concentration-time curve (A 1 ϩ A 2 ; see below). The shape of the first pass concentration-time curve, including all data before evidence of ICG recirculation, was log-linearly described by the sum of two Erlang functions, each representing the convolution of n 1 -compartment models connected in series 17
where n 1 and n 2 are the number of compartments in series in the central delay elements; k 1 and k 2 are the rate constants between the compartments in series; n 1 /k 1 and n 2 /k 2 are the mean transit times (MTT) of the central delay elements; A 1 and A 2 are the areas under the first pass concentration time curves. The two Erlang functions were fitted to the data using the solver function in Excel (Microsoft Corporation, Seattle, WA), whereby data were uniformly weighted. TBV was estimated as TBV ϭ D/C 0 , in which D is the dose administered and C 0 is the log-linearly backextrapolated concentration at MTT, when first mixing but no elimination of ICG has occurred during the first circulation. The intrathoracic or CBV is determined as the product of CO and MTT.
Statistical Analysis
Comparison of the two methods in both groups (nose and finger probe) was done by Bland-Altman analysis, 18 reporting mean difference (bias) and Limits of Agreement (LOA, bias Ϯ 2 sd). In the group using the finger probe, the total variance due to intra-and interindividual differences was considered using additional one way analysis of variance. 19 Comparison of ICG peak concentrations using the finger or nose probe versus the arterial blood ICG concentration was performed by a paired T-test (SPSS, version 14.0).
RESULTS
Patients
Patient characteristics of both groups are represented in Table 1 .
ICG Concentration Curves
In both sets of patients, it regularly proved difficult to obtain an adequate signal quality.
In two sessions performed with the finger probe, the generated ICG curves consisted of a small-based concentration peak, generating CBV of 22.7 and 26.8 L and an accordingly high CO of 35 and 47.3 L/min. Since these figures were far beyond physiologically acceptable values, the results for CO and CBV were excluded from the Bland-Altman analysis.
Because of the rapid arterial blood sampling it was possible to obtain an adequate number of data points to define the peak in the arterial ICG concentration, including recirculation of the dye. In each experiment, on average, 32 arterial blood samples for blood ICG concentration determination were taken, of which 20 were in the first minute. In both groups, the peak blood ICG concentration measured by PDD was generally higher than in the arterial blood with an average difference of ϩ29% Ϯ 36% (mean Ϯ sd) using the finger probe (n ϭ 24, P Ͻ 0.001) and ϩ 34.2% Ϯ 46.5% (mean Ϯ sd) using the nose probe (n ϭ 9, P ϭ 0.079). Furthermore, the peak concentration of ICG measured by PDD lagged behind the arterial blood ICG peak concentration. The average time shift between the noninvasively and invasively measured ICG concentration was 9.6 s Ϯ 9 (sd) in the finger probe group. In the nose probe group, this time shift did not occur. Examples of ICG concentration curves showing a marked difference in MTT between invasive and noninvasive ICG measurements using the finger probe are shown in Figure 1 . The data were obtained from the same patient in successive sessions. In this case, no clear differences in peak concentrations were observed.
Hemodynamic Variables Using the Finger Probe
In 24 datasets, the CO and CBV and in 26 datasets TBV were calculated and compared. TBV was recalculated from the raw data, using a spreadsheet with the algorithms as described in the Methods section, to correct for major noise artifacts by adjusting the interval of the curve used for back-extrapolation to C 0 . The Bland-Altman analysis revealed a mean absolute difference and LOA between PDD and invasive measurements for CO of Ϫ0.43 L/min (Ϫ4.76 and 3.90 L/min); for CBV of 0.76 L (Ϫ2.45 and 3.97 L) and for TBV of Ϫ1.42 L (Ϫ3.88 and 1.03 L) (Fig. 2) . The Bland-Altman analysis revealed a mean relative difference and LOA between PDD and invasive measurements for CO of Ϫ5% (Ϫ56% and 47%); for CBV of 21% (Ϫ54% and 96%) and for TBV of Ϫ15% (Ϫ38% and 8%).
Hemodynamic Variables Using the Nose Probe
In all data sets (n ϭ 10), the CO, CBV and TBV were compared.
The Bland-Altman analysis revealed an absolute bias and LOA between PDD and invasive measurements for CO of 2.26 L/min (Ϫ4.67 and 9.20 L/min); for CBV of 0.79 L (Ϫ2.08 and 3.66 L) and for TBV of Ϫ0.73 L (Ϫ3.48 and 2.01 L) (Fig. 3) . The Bland-Altman analysis revealed a mean relative difference and LOA between PDD and invasive measurements for CO of 30% (Ϫ67% and 127%); for CBV of 48% (Ϫ98% and 193%) and for TBV of Ϫ10% (Ϫ47% and 27%).
DISCUSSION
Various studies on the comparison of PDD-derived cardiovascular variables versus intravascular measurements by e.g., a pulmonary artery catheter have been published: on CO, 3,20 -23 CBV (or intrathoracic), 4 TBV, 13 and hepatic blood flow. 24 The noninvasively derived dye dilution curve was not validated in any of these publications, yet the derived variables were compared with results obtained by other methods of measurement. In other words, no study accurately compared frequently gathered arterial ICG concentrations before complete mixing had occurred with the noninvasive ICG data by PDD and evaluated the derived cardiovascular variables based on these invasive and noninvasive ICG dilution methodologies.
In this study, we evaluated the hemodynamic variables based on noninvasive ICG measurements by PDD, using a finger or nose probe, and compared them to those based on invasive ICG measurements in the arterial blood. Arterial measurement of ICG concentrations is not considered to be the "gold standard" for the determination of cardiovascular variables. However, comparison of these two methods is the most accurate way to evaluate the underlying technique used in PDD. Hence, Bland-Altman analysis of the results is the only allowed method for comparison of the results. The data in the first part of this study were gathered using the finger probe; initially this probe was chosen because the anatomical proximity of the two sample sites (the radial artery and the index finger) was likely to improve the comparability of the data. To improve the comparison, we included a second patient group using the nose probe. For determination of TBV and the ICG disappearance rate (k), both probes generally are considered equally reliable. 5, 6, 14 Some studies, however, suggest that the nose probe may be more reliable for determination of CO, 21 whereas other studies do not favor either probe for CO determination. 13, 15 Our results show an overestimation of CO by the nose probe and underestimation by the finger probe. Providing physiopathological support for this finding is difficult. One can speculate that the influence of vasoconstriction in the microvasculature, tissue volume at the probe site and the proportion of mixed tissue absorption in the digits is more elaborate than in the nasal wing.
We conclude that transcutaneous measurements by PDD result in higher (finger and nose probe) and postponed (finger probe) ICG concentrations compared with arterial ICG concentration measurements of the same bolus of ICG. Any difference in detection of ICG peak concentration has influence on both CO and CBV calculation, as it affects the area under curve (AUC). The phase shift is of consequence in the calculation of CBV, since it directly affects the MTT. Therefore, the PDD-derived hemodynamic variables CO and CBV are inaccurate. As a consequence of the wide LOA, in an individual patient with a CO of 6 L/min, PDD could measure a CO of 3 or 9 L/min. This huge uncertainty significantly limits the use of PDD for the monitoring of CO in the individual patient.
The measurements of TBV correlated better. This can be explained by the fact that TBV is less influenced by a time shift in the first circulation curve, as long as the elimination curve compares well between the two methods. Before accepting a PDD-generated TBV value, we recommend taking the complete concentration curve into consideration: when (motion) artifacts occur in the interval used for back-extrapolation, estimation of the down slope may be highly affected and manual adjustment of the interval is necessary.
The clinical conditions, under which the two probes were tested, varied among subjects in the two studies. At higher ranges of the variables determined, the relative differences between the methods did not show an increase. The magnitude of the bias is therefore not related to the range of CO or TBV in our study.
Study Limitations:
Ideally, the comparison of the two probes would have been performed in a randomized crossover manner, but because of the separate protocols and preoperative character of the experiments, this was not possible. Unfortunately, it was not possible to use both probes simultaneously.
Underestimation of the peak ICG concentration by arterial sampling may, in part, be explained by the lower sample frequency. However, even when smoothing of the curve by a moving average is assumed, the influence on the AUC should be minimal. Furthermore, the gathering of 6 -8 arterial blood samples during the first circulation of ICG (usually 12-20 s) is the maximum achievable in practice. Variability in the ICG measurements in blood was low. In some cases, however, it was more difficult to fit the first circulation. This could occur in patients with a high CO, generating fewer data points in the first circulation of the dye.
In our study, two sessions performed with the finger probe were excluded in the Bland-Altman analysis for CO and CBV. The detected PDD concentration curves showed a small-based peak during the first circulation, generating a very small AUC. The results for CO and CBV were over 20 L (per min) and clearly wrong. Incorrect detection of the PDD may lie in the signal: noise ratio being influenced by motion or low pulsatility of the signal due to constriction of the microvasculature in the digit. The signal may even be merely a reflection of a mixed tissue level due to the passage of the indicator through small arterioles, capillaries, and small veins. There was, however, no obvious reason for the findings in these sessions. Bremer et al. 20 report an average of five performed measurements by PDD to collect three apparently valid recordings, Haruna et al. 6 excluded 3 of 10 volunteers due to motion artifacts and/or low signal: noise ratio. In cases in which the declining part of the concentration peak is not smooth, the PDD device may generate an inadequate fit of the first circulation. This cannot be adjusted manually.
We recommend that the (future) user of the PDD method pay attention to the following aspects: optimize signal quality by guarding the temperature of the probe site, avoid vasoconstriction, avoid excess light at the probe site, avoid motion of the patient or probe, check the signal quality during the measurement (aim for a minimum of two of five U on the display), observe the concentration curve for adequacy of fit of the first circulation, and adjust the interval for backextrapolation, if necessary.
CONCLUSION
In conclusion, the results of this study significantly question the reliability of the PDD method tested in Vol. 109, No. 2, August 2009 this study for measuring CO and CBV measurement in the individual patient. The nose and finger probe were equally unreliable. Given the wide LOA, PDD could misinform the clinician about the patient's actual hemodynamic status. Despite the need for less invasive methods of CO measurement, better alternatives than PDD are required. PDD is better suited for measurement of TBV, as our findings indicate. PDD is also used as an indicator for hepatic clearance and hepatic blood flow, especially during liver transplantation. 24 -26 The application of PDD for this purpose remains to be validated.
